CYP4Z1
Cytochrome P450 4Z1
Also known as: CP4Z1_HUMAN, CYP4A20
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q86W10
- Gene
- CYP4Z1
- Ensembl
- ENSG00000186160
- Chromosome
- 1
- Canonical length
- 505 aa
- Protein class
- Enzymes, Metabolic proteins, Predicted membrane proteins
OverviewNCBI Gene
This gene encodes a member of the cytochrome P450 superfamily of enzymes. The cytochrome P450 proteins are monooxygenases which catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. This gene is part of a cluster of cytochrome P450 genes on chromosome 1p33. [provided by RefSeq, Jul 2008]
Canonical amino-acid sequenceUniProt
505 residues, UniProt reviewed canonical sequence.
>Q86W10|CYP4Z1
1 MEPSWLQELM AHPFLLLILL CMSLLLFQVI RLYQRRRWMI RALHLFPAPP AHWFYGHKEF
61 YPVKEFEVYH KLMEKYPCAV PLWVGPFTMF FSVHDPDYAK ILLKRQDPKS AVSHKILESW
121 VGRGLVTLDG SKWKKHRQIV KPGFNISILK IFITMMSESV RMMLNKWEEH IAQNSRLELF
181 QHVSLMTLDS IMKCAFSHQG SIQLDSTLDS YLKAVFNLSK ISNQRMNNFL HHNDLVFKFS
241 SQGQIFSKFN QELHQFTEKV IQDRKESLKD KLKQDTTQKR RWDFLDILLS AKSENTKDFS
301 EADLQAEVKT FMFAGHDTTS SAISWILYCL AKYPEHQQRC RDEIRELLGD GSSITWEHLS
361 QMPYTTMCIK ECLRLYAPVV NISRLLDKPI TFPDGRSLPA GITVFINIWA LHHNPYFWED
421 PQVFNPLRFS RENSEKIHPY AFIPFSAGLR NCIGQHFAII ECKVAVALTL LRFKLAPDHS
481 RPPQPVRQVV LKSKNGIHVF AKKVCLocalizationUniProt · AlphaFold · HPA
Whether an antibody against CYP4Z1 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Other membrane
- Secreted
- No
- Transmembrane segments
- 1
- Mean surface accessibility (rSASA)
- 0.24
- Highest tissue expression
- 5.2 nTPM
Expression across tissuesHPA
Tissue
- breast: 5.2 nTPM
- adipose tissue: 1.8 nTPM
- lung: 1.3 nTPM
- hypothalamus: 1.2 nTPM
- prostate: 1 nTPM
- cerebral cortex: 0.8 nTPM
Single-cell type
- fibro-adipogenic progenitors: 54 nCPM
- breast myoepithelial cells: 37 nCPM
- epicardial cells: 34 nCPM
- breast hormone-responsive cells: 22 nCPM
- retinal ganglion cells: 16 nCPM
- prostatic hillock cells: 13 nCPM
Immune cell
- basophil: 0 nTPM
- classical monocyte: 0 nTPM
- eosinophil: 0 nTPM
- gdT-cell: 0 nTPM
- intermediate monocyte: 0 nTPM
- MAIT T-cell: 0 nTPM
Brain region
- hypothalamus: 4.2 nTPM
- cerebral cortex: 3.9 nTPM
- basal ganglia: 3.4 nTPM
- white matter: 3.4 nTPM
- amygdala: 3.1 nTPM
- medulla oblongata: 2.3 nTPM
ReferencesPubMed · IEDB
Publications for CYP4Z1 from three distinct lines of evidence, kept separate because they answer different questions: whether antibodies are directed at the protein, whether a B-cell epitope has been mapped on it, and whether a T-cell epitope has. Each is labelled with its source.
Reference: AutoantibodyPubMed
2 publications
- Anti-CYP4Z1 autoantibodies detected in breast cancer patients.
2017 · Cell Mol Immunol · RCR 1.2 · 32 citations - Monitoring of autoantibodies against CYP4Z1 in patients with colon, ovarian, or prostate cancer.
2022 · Immunobiology · RCR 0.5 · 5 citations
Sources: PubMed — antigen-level antibody evidence from a custom retrieval. Records matching a controlled set of autoantibody terms (the MeSH descriptors Autoantibodies and Autoantigens, with title and abstract term variants) were obtained through NCBI E-utilities, and their titles and abstracts parsed for constructions that direct an antibody at a named protein rather than for co-occurrence. Captured names were resolved against UniProt nomenclature and each antigen adjudicated individually against the source text. Bibliographic records from PubMed and MeSH, U.S. National Library of Medicine; citation metrics from NIH iCite (Hutchins et al., PLoS Biology 2016). Titles link to PubMed; abstracts are not reproduced here. The NLM does not endorse this analysis.
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 1.46
- gnomAD pLI
- 0
- gnomAD missense Z
- 0.11
- DepMap mean gene effect
- -0.02
- DepMap dependency class
- none
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
Molecular functions
- arachidonate 14,15-epoxygenase activity
- heme binding
- iron ion binding
- oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
- fatty acid in-chain hydroxylase activity
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads CYP4Z1 as an antibody target. Whether an autoantibody or antibody against CYP4Z1 could matter depends on whether native CYP4Z1 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
CYP4Z1 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label CYP4Z1 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...